Full text is available at the source.
Using lipid nanoparticles to deliver GM-CSF for autoimmune lung disease causing protein buildup
Updated
Abstract
Essence
Nebulized GM-CSF mRNA lipid nanoparticles may restore macrophage surfactant clearance in a preclinical aPAP model.
Evidence
Preclinical lipid nanoparticle design and disease-model experiments tested NLD2 delivery of GM-CSF mRNA to alveolar macrophages and surfactant lipoprotein clearance.
Caveat
The evidence remains preclinical, with no patient safety, dosing, durability, or clinical outcome data for nebulized NLD2 GM-CSF mRNA.
Simplified
mRNA Technology